SG11202105573PA - Methods of treating myelodysplastic syndrome - Google Patents

Methods of treating myelodysplastic syndrome

Info

Publication number
SG11202105573PA
SG11202105573PA SG11202105573PA SG11202105573PA SG11202105573PA SG 11202105573P A SG11202105573P A SG 11202105573PA SG 11202105573P A SG11202105573P A SG 11202105573PA SG 11202105573P A SG11202105573P A SG 11202105573PA SG 11202105573P A SG11202105573P A SG 11202105573PA
Authority
SG
Singapore
Prior art keywords
methods
myelodysplastic syndrome
treating myelodysplastic
treating
syndrome
Prior art date
Application number
SG11202105573PA
Inventor
Aleksandra Rizo
Jacqueline Cirillo Bussolari
Fei Huang
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of SG11202105573PA publication Critical patent/SG11202105573PA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57426Specifically defined cancers leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • G01N2333/91245Nucleotidyltransferases (2.7.7)
    • G01N2333/9125Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
    • G01N2333/9128RNA-directed DNA polymerases, e.g. RT (2.7.7.49)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202105573PA 2018-11-29 2019-11-26 Methods of treating myelodysplastic syndrome SG11202105573PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862772861P 2018-11-29 2018-11-29
US201962811271P 2019-02-27 2019-02-27
US201962860557P 2019-06-12 2019-06-12
PCT/US2019/063372 WO2020112854A1 (en) 2018-11-29 2019-11-26 Methods of treating myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
SG11202105573PA true SG11202105573PA (en) 2021-06-29

Family

ID=70849825

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105573PA SG11202105573PA (en) 2018-11-29 2019-11-26 Methods of treating myelodysplastic syndrome

Country Status (14)

Country Link
US (1) US20200171072A1 (en)
EP (1) EP3887537A4 (en)
JP (2) JP2022513162A (en)
KR (1) KR20210110303A (en)
CN (1) CN113631719A (en)
AU (1) AU2019389005A1 (en)
BR (1) BR112021010406A2 (en)
CA (1) CA3120704A1 (en)
CL (1) CL2021001386A1 (en)
IL (1) IL283054A (en)
MX (1) MX2021006131A (en)
SG (1) SG11202105573PA (en)
TW (1) TW202038973A (en)
WO (1) WO2020112854A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116189765B (en) * 2023-02-23 2023-08-15 上海捷易生物科技有限公司 iPS cytogenetic risk assessment system and application

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8460872B2 (en) * 2011-04-29 2013-06-11 Sequenom, Inc. Quantification of a minority nucleic acid species
US20150005250A1 (en) * 2011-10-13 2015-01-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Telomerase reverse transcriptase deficiency as diagnostic marker of myelodysplastic syndrome
US9375485B2 (en) * 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
WO2019023667A1 (en) * 2017-07-28 2019-01-31 Janssen Biotech, Inc. Methods of treating myelodysplastic syndrome

Also Published As

Publication number Publication date
MX2021006131A (en) 2021-06-23
AU2019389005A1 (en) 2021-06-24
JP2023016965A (en) 2023-02-02
TW202038973A (en) 2020-11-01
IL283054A (en) 2021-06-30
BR112021010406A2 (en) 2021-08-24
US20200171072A1 (en) 2020-06-04
WO2020112854A1 (en) 2020-06-04
CA3120704A1 (en) 2020-06-04
EP3887537A4 (en) 2023-04-12
EP3887537A1 (en) 2021-10-06
KR20210110303A (en) 2021-09-07
CL2021001386A1 (en) 2021-12-10
JP2022513162A (en) 2022-02-07
CN113631719A (en) 2021-11-09

Similar Documents

Publication Publication Date Title
HRP20181661T1 (en) Jak1 inhibitors for the treatment of myelodysplastic syndromes
ZA202006746B (en) Methods of treatment
IL269371A (en) Treatment methods
GB201804514D0 (en) Treatment of pyroptosis
EP3634369C0 (en) Methods for treating chemically relaxed hair
ZA201808607B (en) Methods of treating prader-willi syndrome
IL265342A (en) Use of pridopidine for treating rett syndrome
GB201813876D0 (en) Treatment
IL272092A (en) Methods of treating behavior alterations
PL3625375T3 (en) Surface treatment of turbomachinery
EP3894768C0 (en) Methods of cryo-curing
IL281792A (en) Treatment methods
GB201804515D0 (en) Treatment of necroptosis
GB201800546D0 (en) Treatment
IL272163A (en) Methods of treating myelodysplastic syndrome
IL281839A (en) Treatment methods
IL283054A (en) Methods of treating myelodysplastic syndrome
SG11202105877YA (en) Method of treatment
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB2580157B (en) Treatment of produced hydrocarbons
GB2580145B (en) Treatment of produced hydrocarbons
GB201801249D0 (en) Methods of treatment
IL281595A (en) Treatment of cholangiocarcinoma
ZA201906319B (en) Methods of treating depression
GB201814905D0 (en) Treatment